Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The International Workshop on Non-Hodgkin Lymphoma (iwNHL) was established in 2001 to encourage interactive debates and discussions on non-Hodgkin lymphoma (NHL) and related disorders in a workshop environment.

The 14th International Workshop on Non-Hodgkin Lymphoma will be held in San Diego, California.

iwNHL 2016

23–25 September 2016 | Hotel Del Coronado in San Diego

iwNHL 2016

23–25 September 2016 | Hotel Del Coronado in San Diego

The International Workshop on Non-Hodgkin Lymphoma (iwNHL) was established in 2001 to encourage interactive debates and discussions on non-Hodgkin lymphoma (NHL) and related disorders in a workshop environment.

The 14th International Workshop on Non-Hodgkin Lymphoma will be held in San Diego, California.

An overview of iwNHL 2016 by Prof. Anas Younes 1:09
An overview of iwNHL 2016 by Prof. Anas Younes
Anas Younes • 3 Jun 2016
iwNHL 2016: Highlights from Day 1 21:39
iwNHL 2016: Highlights from Day 1
Catherine Bollard et al. • 24 Sep 2016
iwNHL 2016: Highlights from Day 2 26:58
iwNHL 2016: Highlights from Day 2
Anas Younes et al. • 25 Sep 2016
iwNHL 2016 highlights: CAR T-cell therapy, DLBCL and new technologies 2:56
iwNHL 2016 highlights: CAR T-cell therapy, DLBCL and new technologies
Andrew Davies • 23 Sep 2016
Targeted molecular signatures of DLBCL and upcoming CheckMate 647 trial for PCNSL and PTL 4:01
Targeted molecular signatures of DLBCL and upcoming CheckMate 647 trial for PCNSL and PTL
Bjoern Chapuy • 23 Sep 2016
Results of trial on the use of interim PET scan to identify DLBCL 3:06
Results of trial on the use of interim PET scan to identify DLBCL
Laurie Sehn • 23 Sep 2016
Upcoming trials for DLBCL: R-CHOP with acalabrutinib and obinutuzumab with checkpoint inhibitor 2:56
Upcoming trials for DLBCL: R-CHOP with acalabrutinib and obinutuzumab with checkpoint inhibitor
Andrew Davies • 23 Sep 2016
Discussion of the two biologies of DLBCL – the GCB and ABC subtype and potential targeted therapies 1:53
Discussion of the two biologies of DLBCL – the GCB and ABC subtype and potential targeted therapies
Clemens Schmitt • 23 Sep 2016
Current projects at City of Hope: CAR T-cells, vaccines and a novel nuceloside analogue 2:12
Current projects at City of Hope: CAR T-cells, vaccines and a novel nuceloside analogue
Steven Rosen • 23 Sep 2016
The standard of care for DLBCL and double-hit lymphoma 1:34
The standard of care for DLBCL and double-hit lymphoma
Laurie Sehn • 23 Sep 2016
The potential clinical implications of targeted therapies for DLBCL and why the situation is complex 1:47
The potential clinical implications of targeted therapies for DLBCL and why the situation is complex
Clemens Schmitt • 23 Sep 2016
The work and mission of City of Hope 1:32
The work and mission of City of Hope
Steven Rosen • 23 Sep 2016
Panel discussion on T-cell lymphoma: current status of therapy and progress 13:37
Panel discussion on T-cell lymphoma: current status of therapy and progress
Elaine Jaffe et al. • 23 Sep 2016
Panel discussion on large cell lymphomas: subtypes, patient selection and mutations 12:46
Panel discussion on large cell lymphomas: subtypes, patient selection and mutations
Andrew Zelenetz et al. • 23 Sep 2016
Novel immunotherapies and liquid biopsies – highlights from iwNHL 2016 1:31
Novel immunotherapies and liquid biopsies – highlights from iwNHL 2016
Anton Hagenbeek • 23 Sep 2016
Progress in mantle cell lymphoma over the last 15 years 3:03
Progress in mantle cell lymphoma over the last 15 years
Marek Trněný • 23 Sep 2016

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals